Glenmark Pharmaceuticals has appointed Kurt Stoeckli as President and Chief Scientific Officer (CSO) of the company.
He will also be the President and General Manager of Glenmark's Switzerland-based business units. He will lead the company's global research portfolio consisting of NBE, NCE, generics and branded formulations, Glenmark Pharmaceuticals said in a statement.
Stoeckli will be responsible for sustaining and enhancing the environment of collaborative research and for driving successful commercialisation of Glenmark's research pipeline in partnership with other leaders, it added.
He joins the company from Sanofi where he was Group Vice President, Global Biopharmaceuticals Division and Chief Scientific Officer for Research and Development France, Glenmark Pharmaceuticals said in a statement.
Stoeckli will report to Glenn Saldanha and will be based out of Neuchatel, Switzerland.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
